Complement activation by beta-amyloid in Alzheimer disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 1438191.
- Also identified by PMC identifier 50268.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alzheimer disease (AD) is characterized by excessive deposition of the beta-amyloid peptide (beta-AP) in the central nervous system. Although several lines of evidence suggest that beta-AP is neurotoxic, a mechanism for beta-AP toxicity in AD brain remains unclear. In this paper we provide both direct in vitro evidence that beta-AP can bind and activate the classical complement cytolytic pathway in the absence of antibody and indirect in situ evidence that such actions occur in the AD brain in association with areas of AD pathology.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Brain
- Complement Activation
- Complement Pathway, Classical